JP7566731B2 - Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 - Google Patents

Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Download PDF

Info

Publication number
JP7566731B2
JP7566731B2 JP2021522931A JP2021522931A JP7566731B2 JP 7566731 B2 JP7566731 B2 JP 7566731B2 JP 2021522931 A JP2021522931 A JP 2021522931A JP 2021522931 A JP2021522931 A JP 2021522931A JP 7566731 B2 JP7566731 B2 JP 7566731B2
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
optionally substituted
group
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529833A5 (enExample
JP2021529833A (ja
Inventor
ウィリアム アール． ラウシュ
シャンカー ヴェンカトラマン
ゲイリー グリック
ハンス マーティン シーデル
Original Assignee
アイエフエム デュー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイエフエム デュー インコーポレイテッド filed Critical アイエフエム デュー インコーポレイテッド
Publication of JP2021529833A publication Critical patent/JP2021529833A/ja
Publication of JP2021529833A5 publication Critical patent/JP2021529833A5/ja
Priority to JP2024094148A priority Critical patent/JP2024116295A/ja
Application granted granted Critical
Publication of JP7566731B2 publication Critical patent/JP7566731B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021522931A 2018-07-03 2019-07-02 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Active JP7566731B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094148A JP2024116295A (ja) 2018-07-03 2024-06-11 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693768P 2018-07-03 2018-07-03
US62/693,768 2018-07-03
US201962861825P 2019-06-14 2019-06-14
US62/861,825 2019-06-14
PCT/US2019/040317 WO2020010092A1 (en) 2018-07-03 2019-07-02 Compounds and compositions for treating conditions associated with sting activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094148A Division JP2024116295A (ja) 2018-07-03 2024-06-11 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021529833A JP2021529833A (ja) 2021-11-04
JP2021529833A5 JP2021529833A5 (enExample) 2022-07-08
JP7566731B2 true JP7566731B2 (ja) 2024-10-15

Family

ID=67441650

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522931A Active JP7566731B2 (ja) 2018-07-03 2019-07-02 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024094148A Pending JP2024116295A (ja) 2018-07-03 2024-06-11 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094148A Pending JP2024116295A (ja) 2018-07-03 2024-06-11 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Country Status (7)

Country Link
US (2) US11618749B2 (enExample)
EP (1) EP3817820A1 (enExample)
JP (2) JP7566731B2 (enExample)
CN (2) CN120004785A (enExample)
MA (1) MA53095A (enExample)
TW (1) TWI873098B (enExample)
WO (1) WO2020010092A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024116295A (ja) * 2018-07-03 2024-08-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
TW202043198A (zh) * 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
JP2022517797A (ja) * 2019-01-17 2022-03-10 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2020252240A1 (en) * 2019-06-14 2020-12-17 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114761804A (zh) 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
JP2023509421A (ja) 2019-12-31 2023-03-08 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CA3166358A1 (en) * 2020-02-12 2021-08-19 Monali BANERJEE Small molecule sting antagonists
US20230151024A1 (en) * 2020-04-10 2023-05-18 Ono Pharmaceutical Co., Ltd. Sting agonistic compound
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
JP6912016B1 (ja) * 2020-04-10 2021-07-28 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
AU2021381469A1 (en) * 2020-11-23 2023-06-15 Regor Pharmaceuticals, Inc. Sting antagonists and uses thereof
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240060982A1 (en) * 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
JP2024502473A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するためのオキサルアミド化合物および組成物
CN117561253A (zh) 2021-01-08 2024-02-13 艾福姆德尤股份有限公司 用于治疗与sting活性有关的病症的化合物和组合物
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
IL310724A (en) 2021-08-10 2024-04-01 Ifm Due Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY
WO2023017451A1 (en) * 2021-08-11 2023-02-16 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
CN115710255B (zh) * 2021-08-23 2025-05-06 上海交通大学 一类含有苯并杂环取代的脲类衍生物及其制备和用途
CN116789641A (zh) * 2022-03-17 2023-09-22 中国科学院上海药物研究所 二氢异喹啉类化合物及其医药用途
CN119677718A (zh) * 2022-08-11 2025-03-21 杭州中美华东制药有限公司 具有sting抑制作用的酰胺类化合物及其药物组合物和用途
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024089006A1 (en) * 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
JP2026512969A (ja) * 2022-10-26 2026-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｔｉｎｇを活性化することができる複素環式化合物
CA3266173A1 (en) * 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING
CN120476113A (zh) * 2022-12-20 2025-08-12 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
CN120794957A (zh) * 2024-05-14 2025-10-17 中国药科大学 苯并含氮杂环类sting抑制剂及其医药用途
CN121342824A (zh) * 2024-07-16 2026-01-16 中国药科大学 四氢萘啶类sting抑制剂及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
JP2015098482A (ja) 2008-05-13 2015-05-28 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤としてのピロロピリジン
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
BR0212841A (pt) 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
MXPA04011417A (es) 2002-05-17 2005-02-14 Pharmacia Italia Spa Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
JP4648703B2 (ja) * 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
BR0316606A (pt) 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
CA2682016A1 (en) * 2007-03-28 2008-10-02 Inovacia Ab Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
US8497285B2 (en) 2010-12-03 2013-07-30 The Trustees Of The University Of Pennsylvania Therapy of autoimmune colitis using a TIP60 inhibitor
CA2835835C (en) * 2011-05-13 2019-04-02 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
US20170273922A1 (en) * 2014-10-03 2017-09-28 The Royal Institution For The Advacement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
JP2019510802A (ja) * 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
EP3568390B1 (en) 2017-01-10 2024-03-06 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
CN109180649B (zh) 2017-08-18 2021-03-12 四川百利药业有限责任公司 一种含吲哚环的ido抑制剂及其制备方法
WO2019122202A1 (en) 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
EP3556362A1 (en) 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
JP7482122B2 (ja) 2018-07-03 2024-05-13 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN120004785A (zh) 2018-07-03 2025-05-16 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
JP2022507697A (ja) 2018-11-19 2022-01-18 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2020106741A1 (en) 2018-11-19 2020-05-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2022517797A (ja) 2019-01-17 2022-03-10 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關之病況的化合物及組合物
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020236586A1 (en) 2019-05-17 2020-11-26 Ifm Due, Inc. N-hetaryl-squaramide compounds for treating conditions associated with sting activity
WO2020243519A1 (en) 2019-05-29 2020-12-03 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020252240A1 (en) 2019-06-14 2020-12-17 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114761804A (zh) * 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
WO2021067791A1 (en) 2019-10-03 2021-04-08 Ifm Due, Inc. Oxalamide compounds and compositions for treating conditions associated with sting activity
UY38905A (es) 2019-10-03 2021-04-30 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
WO2021067801A1 (en) 2019-10-03 2021-04-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN115348957B (zh) 2019-12-31 2025-11-25 诺华制药股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
JP2023509421A (ja) 2019-12-31 2023-03-08 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US20230250088A1 (en) 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20220024919A1 (en) 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PY2157405A (es) 2020-07-15 2022-04-22 Ifm Due Inc Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
JP2023540674A (ja) 2020-07-15 2023-09-26 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US20230250106A1 (en) 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20220024906A1 (en) 2020-07-15 2022-01-27 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
JP2015098482A (ja) 2008-05-13 2015-05-28 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤としてのピロロピリジン
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kumaran, K.; Kamil, S. Raja Mohamed; Jaisankar, K. R.，Synthesis, spectral characterization and antimicrobial studies of new 3- and 4-substituted in 7-azaindole derivatives，International Journal of PharmTech Research ，2012年，4(1),，169-175
Ried, Walter et al.，Synthesis of thieno[2,3-d]pyrimidines and pyrrolo[2,3-d]pyrimidines，Liebigs Annalen der Chemie ，1988年，(7),，633-42
Zhang, Jing et al.，Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors，Journal of Medicinal Chemistry ，2015年，58(21),，8503-8512

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024116295A (ja) * 2018-07-03 2024-08-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Also Published As

Publication number Publication date
JP2024116295A (ja) 2024-08-27
US20200172534A1 (en) 2020-06-04
CN112823036A (zh) 2021-05-18
CN120004785A (zh) 2025-05-16
JP2021529833A (ja) 2021-11-04
TWI873098B (zh) 2025-02-21
CN112823036B (zh) 2024-11-08
TW202014408A (zh) 2020-04-16
MA53095A (fr) 2021-05-12
EP3817820A1 (en) 2021-05-12
US11618749B2 (en) 2023-04-04
WO2020010092A1 (en) 2020-01-09
US20240083895A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
JP7566731B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7482122B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7756643B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2025037981A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN115279770A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
WO2020150417A2 (en) Compounds and compositions for treating conditions associated with sting activity
JP2025066719A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2020106741A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2022535743A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2023540673A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
US20230002373A1 (en) Compounds and compositions for treating conditions associated with sting activity
EP3911314A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
JP2023540674A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502472A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2022015938A1 (en) Compounds and compositions for treating conditions associated with sting activity
US20250136597A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2024502470A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2024064358A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2025503675A (ja) Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
JP2024502473A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するためのオキサルアミド化合物および組成物
JP2023554392A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2025504415A (ja) Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
HK40048005B (zh) 用於治疗与sting活性有关的疾病的化合物和组合物
HK40048005A (en) Compounds and compositions for treating conditions associated with sting activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7566731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02